FDA Updates Draft Guidance on Promotional Communications of Prescription Biologics and Biosimilars | Goodwin

On April 25, 2024, the FDA published a notice of availability in the Federal Register for its revised draft guidance, entitled “Promotional Labeling and Advertising Considerations for...

Related Keywords

,Public Health Service ,Draft Guidance ,Promotional Communications ,Prescription Biologics ,Federal Register ,Advertising Considerations ,Prescription Biological Reference Products ,Biosimilar Products ,Interchangeable Biosimilar Products ,